Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733398 | 0.88 | ACLY (0.43) | AKR1B1ACLYNOTUMCYP3A4CYP2D6 | |
| SCHEMBL30733427 | 0.86 | ACLY (0.42) | AKR1B1ACLYNOTUMCYP3A4CYP2D6 | |
| SCHEMBL30733423 | 0.86 | KCNN4 (0.47) | AKR1B1ACLYNOTUMPOLB | |
| SCHEMBL30733401 | 0.86 | NOTUM (0.45) | ACLYNOTUMCYP3A4CYP2D6NPY5R | |
| SCHEMBL26969734 | 0.83 | MMP2 (0.44) | AKR1B1ACLYNOTUMCYP3A4CYP2D6 | |
| SCHEMBL25238614 | 0.82 | NOTUM (0.42) | ACLYNOTUMPOLBCYP3A4CYP2D6 | |
| SCHEMBL25285056 | 0.82 | MMP2 (0.43) | AKR1B1ACLYNOTUMCYP3A4CYP2D6 | |
| SCHEMBL26969767 | 0.81 | ALDH1A1 (0.49) | NOTUMNPY5R | |
| SCHEMBL26969716 | 0.81 | ACLY (0.44) | ACLYNOTUMNPY5R | |
| SCHEMBL26969782 | 0.81 | NOTUM (0.41) | ACLYNOTUMCYP3A4CYP2D6NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | AKR1B1 3537/4885KDM2B 3104/4885ACLY 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.